Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Incyte (INCY)

Incyte reshuffles executive team; Cagnoni named President, Meury stays CEO

Neutral Impact 3 of 5 leadership Written later

Incyte announced title changes for four executives effective March 25, 2026. Pablo Cagnoni became President and Global Head of Research and Development, replacing William Meury as President while Meury remains Chief Executive Officer and a board member. The company said there were no changes to compensation arrangements for the affected executives.

Key points

  • Pablo J. Cagnoni named President, Incyte and Global Head of Research and Development, replacing William J. Meury as President
  • William J. Meury remains Chief Executive Officer and a member of the Board of Directors
  • Mohamed Issa's U.S. Oncology and U.S. Immunology businesses are being integrated into a single U.S. commercial organization
  • Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period

The filing

CompanyIncyte (INCY)
Form8-K, current report
Filed with the SECMar 26, 2026, 8:38 AM ET
Accession number0000879169-26-000016

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.